More on PHAT

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (+33.3% Growth)
- Ratings (8.6 Score)
- FDA

Upcoming Events

- Earnings (11/5/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Phathom Pharmaceuticals Inc. (NQ:PHAT)
Delayed: 6.92 -0.58 (7.73%)
Prev. Close $7.50  
Open$7.51 
52 Wk High$ 
52 Wk Low$ 
Day High$7.57 
Day Low$6.90 
P/E N/A  
EPS$ 
Volume1,254,291 

Friends, Peers and Foes (?): 2RH, CPIX RDHL (more...)

Oct 14, 2026 04:53 AM Phathom Pharmaceuticals (PHAT) PT Lowered to $16 at Jefferies
Oct 12, 2026 08:03 AM Phathom data projects vonoprazan cost-effective vs. PPIs for GERD
Oct 12, 2026 08:00 AM Phathom Pharmaceuticals Highlights New Cost-Effectiveness Data and Growing Clinical Interest in VOQUEZNA® (vonoprazan) at ACG 2026
Oct 8, 2026 05:45 PM Form 4 Phathom Pharmaceuticals, For: Oct 06 Filed by: Narula Sanjeev
Oct 8, 2026 08:00 AM Phathom to present Voquezna data at ACG 2026 meeting
Oct 8, 2026 08:00 AM Phathom Pharmaceuticals to Present New Data and Analyses for VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting
Sep 29, 2026 04:46 PM Form 8-K Phathom Pharmaceuticals, For: Sep 29
Sep 29, 2026 08:00 AM Phathom starts Phase 3 trial of Voquezna for on-demand GERD use
Sep 29, 2026 08:00 AM Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of VOQUEZNA® (vonoprazan) for As-Needed Treatment of Non-Erosive GERD
Sep 9, 2026 06:11 AM Leerink Starts Phathom Pharmaceuticals (PHAT) at Market Perform
View All Articles

Entities mentioned with PHAT

View All Entities